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Drug-eluting stents have significantly improved the treatment of coronary artery disease. They offer
reduced rates of restenosis compared with their bare-metal predecessors and are the current gold standard
in percutaneous coronary interventions. Drug-eluting stents have been approved for use in humans since
2002 and yet, despite the intensive research activity over the past decade, the drug release mechanism(s)
and the uptake into the arterial wall are still poorly understood. While stent manufacturers have focussed
primarily on empirical methods, several mathematical models have appeared in the literature considering
the release problem, the uptake problem and also the coupled problem. However, two significant chal-
lenges that remain are in understanding the drug release mechanism(s) and also the determination of the
various parameters characterizing the system. These include drug diffusion coefficients and dissolution
constants in the stent polymer coating as well as drug diffusion coefficients, binding/uptake rates and the
magnitude of the transmural convection in the arterial wall. In this paper we attempt to address these
problems. We provide analytical solutions which, when compared with appropriate experiments, may
allow the various parameters of the system to be estimated via the inverse problem. The analytical solu-
tions which we provide here for drug release in vitro may thus be used as a tool for providing insights
into the mechanism(s) of release.
Keywords: drug-eluting stents; analytical solutions; parameter estimation; inverse problem.
1. Introduction
An arterial stent is a small scaffold-like medical device used to increase the size of the lumen when it
has become narrowed due to the formation of atherosclerotic plaque. These stents are now routinely
coated with a drug to counteract the inflammatory response following insertion into the diseased artery.
Compared with their bare metal predecessors, the so-called drug-eluting stents (DESs) offer reduced
rates of restenosis and thus represent the current gold standard in percutaneous coronary interventions.
While DESs have been around for over a decade, the drug release mechanism(s) and the uptake into the
arterial wall are still poorly understood.
c© The Authors 2014. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications.
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The problem of modelling drug release from arterial stents was presented at the fourth UK Math-
ematics in Medicine Study Group (see Green et al., 2005) and many publications on this topic have
appeared in the literature to date. One of the most important aspects in the performance of DESs is the
drug release profile. Owing to the expense and time associated with in vivo experiments, stent manu-
facturers routinely test the release of drug from their stents in an in vitro environment. While this is
unlikely to replicate the in vivo situation, where flowing blood, pulsatility, wound healing, proliferation,
migration of cells and complex uptake/binding no doubt all play some part, it nonetheless provides the
manufacturer with an idea of the shape of the release profile and allows for comparison between dif-
ferent stent designs. Furthermore, it allows the manufacturer to test the quality of the product and the
repeatability of the release profile. While stent manufacturers primarily use empirically based meth-
ods, when coupled with appropriate modelling, the in vitro experiments may provide insights into the
mechanism(s) of release: this is a topic of some controversy in the literature with diffusion, dissolution,
polymer swelling and degradation all of which are cited as possible release mechanisms. Several authors
have attempted to model the drug release from these devices. For example, referring to polymer-coated
DESs which is the focus of this article, Zhao et al. (2012) presented an analytic solution of a cylindri-
cal diffusion model to describe the experimental drug release of everolimus from a Dynalink-E stent
while Hossainy and Prabhu (2008) presented a mathematical model for predicting the drug release from
a DES coating, based on two discrete modes of transport. Most models assume that Fickian diffusion
plays an important role in the release process. Siepmann and Siepmann (2012) in their review on mod-
elling of diffusion-controlled drug delivery provide a series of analytical solutions for drug release from
reservoir and monolithic drug delivery systems, some of which may be applied to DESs under certain
assumptions. Many of their solutions are early or late time approximations, and in some cases steady-
state solutions. A number of authors have focussed on drug release from biodegradable polymers: we
do not consider such polymers in this article, but the reader is referred to Formaggia et al. (2010), Rossi
et al. (2012) and Fredenberg et al. (2011).
In reality, of course, the stent and the arterial wall are a coupled system and this has also received
much attention in the literature, with most of the models necessarily requiring to be solved numerically
due to the complexity of the problem. One exception is the model of Pontrelli and de Monte (2010) who
consider diffusion-based drug release from the stent coupled with a convection–diffusion equation in the
arterial wall which also accounts for drug consumption via a linear reaction. They obtain an analytical
solution through separation of variables and use this to show the effect of the transmural velocity, drug
metabolism and the amount of drug in the tissue. More recently, Pontrelli et al. (2013a) presented a
semi-analytical expression for the drug concentration and mass in each layer of the arterial wall for the
case where the drug must dissolve in the polymer before it can diffuse. Models which incorporate more
sophisticated binding/reaction terms includes those of McGinty et al. (2010), McGinty et al. (2013),
Horner et al. (2010) and Abraham et al. (2013), who all assume an equilibrium reaction. While McGinty
et al. (2013) made some analytical progress, the other authors employed numerical techniques to solve
their equations. Perhaps the most sophisticated model is that of Tzafriri et al. (2012), who provide a
second-order saturable reversible binding model: this model not only requires to be solved numerically,
but also includes a number of parameters which are difficult to measure experimentally.
In most of the models described above, many parameters characterizing the system are required
to be measured, thus posing a great challenge to experimentalists. These include drug diffusion coef-
ficients and dissolution constants in the stent polymer coating as well as drug diffusion coefficients,
binding/uptake rates and the magnitude of the transmural convection in the arterial wall. Values for
these parameters are typically taken from the available data in the literature which encompasses a great
number of studies using different experimental species (for example, rabbit or pig). Furthermore the
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experimental techniques are often quite different. For example, many experiments are conducted in vitro
when the transmural velocity has necessarily been neglected and in many cases ‘lumped diffusion coef-
ficients’, which inherently include such effects as convection and binding, are measured. Thus great care
must be taken to ensure the accurate estimation of the model parameters. In this paper we attempt to
address this problem by providing analytical solutions which, when compared with appropriate exper-
iments, may allow the various parameters of the system to be estimated via the inverse problem. Of
course, the inverse approach we propose here to estimate model parameters may also be applied to
other drug delivery systems, for example, delivery by drug-filled balloons and transdermal patches (see,
for example, Stark et al., 2013; Pontrelli et al., 2013b).
This paper is organized as follows. Firstly we present a collection of models to describe diffusion-
and dissolution-based release of drug from polymer-coated arterial stents in an in vitro environment. The
boundary conditions have been chosen to reflect the conditions maintained in the experiments. All of the
models are solved analytically, providing user-friendly solutions which can be quickly compared with
observed release profiles. It is intended that when used in conjunction with appropriate experimental
data, these solutions should help us to clarify the release mechanism(s) and thus aid in the development
of DESs. By consideration of the inverse problem, the various parameters characterizing the release
may be determined. We then proceed to consider a model of drug transport through the arterial wall.
This model too is solved analytically, providing three interesting characterizations of the solution. We
demonstrate the equivalence of these solutions and, by comparison with experimental data via an inverse
problem, attempt to uncouple and estimate both the tissue drug diffusion coefficient and convection
parameter.
2. Diffusion-based models of drug release
Most of the modelling of drug release from arterial stents in the literature has thus far been concerned
with first generation DESs. These stents typically comprise a stainless steel platform with a drug con-
taining polymer coating attached to the stent struts (Tzafriri et al., 2012; Stefanini & Holmes, 2013).
The philosophy behind this design was not only to allow the drug to be released gradually so as to
avoid toxic levels of drug initially, but also to permit sustained delivery over many weeks. The drugs
used (sirolimus and paclitaxel) are lipophilic and are able to inhibit SMC proliferation and migration.
Drug release from these stents has been modelled as a diffusion-dominated process (see, for example,
McGinty et al., 2010; Pontrelli and de Monte, 2010), with the drug concentration in the polymer Cp
satisfying a diffusion equation with drug diffusion coefficient Dp. Several simplifying assumptions are
made. Firstly, it is assumed that the device geometry is that of a thin film of thickness Lp with no edge
effects so that the modelling may be restricted to one dimension. The diffusion of the drug in the poly-
mer is thus considered to be isotropic and it may be assumed that the diffusion coefficient is independent
of time, space and concentration. Furthermore, the initial drug concentration is usually taken to be uni-
form. For the case of in vitro drug release a zero flux boundary condition is normally assumed at the
impermeable stent boundary and either an infinite sink or Robin-type boundary condition at the interface
with the release medium. If the release medium volume is sufficiently large and is replenished between
sampling times then the infinite sink condition is most appropriate, whereas if the concentration of drug
in the release medium is allowed to build up, the Robin-type condition is preferred. The model is as
follows:
∂Cp
∂t
(x, t)=Dp
∂2Cp
∂x2
(x, t), 0 < x < Lp, t > 0, (2.1)
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subject to
Cp(x, 0)=C0, 0  x  Lp, (2.2)
−Dp
∂Cp
∂x
(0, t)= 0, t > 0, (2.3)
Cp(Lp, t)= 0 or − Dp
∂Cp
∂x
(Lp, t)= γCp(Lp, t), t > 0, (2.4 a,b)
where γ is some constant of proportionality with dimensions ms−1. Of course (2.4a) can be obtained
from (2.4b) by letting γ →∞ which physically means that the flux across the interface is extremely
rapid. For the case of the infinite sink boundary condition, the system (2.1–2.4a) are readily solved using
the method of Laplace transforms (or otherwise) to provide (see, e.g. Crank, 1975)
Cp(x, t)=−
4C0
π
∞∑
n=1
(−1)n
2n− 1 cos
(
(2n− 1)πx
2Lp
)
exp
{
−(2n− 1)2π2Dpt
4L2p
}
. (2.5)
We can obtain the mass of drug per unit area in the polymer, M (t), by integrating Cp(x, t) over
Lp. From this it is straightforward to show that the cumulative fraction of drug released, Mfrac(t)=
1−M (t)/M0, is
Mfrac(t)= 1−
8
π2
∞∑
n=1
1
(2n− 1)2 exp
{
−(2n− 1)2π2Dpt
4L2p
}
, (2.6)
where M0 = LpC0 has been assumed. For the case where the concentration is allowed to rise in the
release medium (i.e. employing (2.4b) rather than (2.4a)), we can again utilize Laplace transforms along
with the Residue Theorem to provide the solution
Cp(x, t)= 2γC0
∞∑
n=1
exp{−Dpα2n t} cos(αnx)
αn[(Dp + γLp) sin (αnLp)+ αnDpLp cos (αnLp)]
, (2.7)
where αn are the roots of
−Dpα sin (αLp)+ γ cos (αLp)= 0.
In this case the cumulative fraction of drug released turns out to be
Mfrac(t)= 1−
2γ
Lp
∞∑
n=1
exp{−Dpα2n t} sin (αnLp)
α2n[(Dp + γLp) sin (αnLp)+ αnDpLp cos (αnLp)]
. (2.8)
In Fig. 1 we compare the release profiles obtained from Equations (2.6) and (2.8). We assume the
typical values of diffusion coefficient and polymer thickness of Dp = 10−16 m2 s−1 and Lp = 10−5 m,
respectively (McGinty et al., 2010). The solution (2.8) is plotted for three values of γ , 10−10 ms−1,
10−11 ms−1 and 10−12 ms−1. It is evident that for the case where the drug is allowed to rise in the release
medium, the release of the drug can be considerably slowed down.
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Fig. 1. Comparison of release profiles for the cases of release medium being replenished (infinite sink) and drug rising in the
release medium (Robin boundary condition). The top profile displays the solution (2.6), while as we move down, the profiles
display the solution of (2.8) with γ = 10−10 ms−1, γ = 10−11 ms−1 and γ = 10−12 ms−1.
3. Diffusion–dissolution-based models of drug release
In the preceding section, we considered models of drug release whereby the drug was assumed to be
free to diffuse. However, this need not be the case. In fact it is common for the drug to be loaded on
the polymer in such a way that the initial concentration exists in two forms: crystalline (bound) and free
(unbound). In this case the drug needs to dissolve before it can freely diffuse. This can be achieved by
the ingress of fluid into the polymer after placement in the release medium. In this section we describe
three models which incorporate aspects of dissolution as well as diffusion. In all of these models we
assume an infinite sink boundary condition.
3.1 Instantaneous dissolution model
In this case we assume that the initial concentration of drug in the polymer exceeds the solubility limit,
say Cs (assumed to be constant). Thus drug exists in a crystalline form and is permitted only to diffuse
after it has dissolved. Where the initial drug concentration is below the solubility limit, C0 < Cs, the
dissolved drug is free to diffuse. In this case the solutions given by (2.5–2.6) describe the concentration
profile and cumulative fraction of drug released. However, if C0 > Cs then there is an excess of drug
which is immobile and must dissolve before diffusion can commence. This problem was first considered
by Higuchi (1961) who derived an expression for the amount of drug absorbed at time t per unit area. He
obtained his solution from geometrical considerations and Fick’s law. A more mathematical approach
has been considered by, among others, Paul & McSpadden (1976). However, these approaches derive a
solution that is only valid until the time at which the concentration of drug throughout the polymer falls
below the solubility, say t= t⋆. Here we provide the complete solution which is valid for all time.
Suppose that there is a small region immediately adjacent to the release medium boundary where the
concentration of drug is less than the solubility, i.e. it is permitted to diffuse. Suppose further that to the
left of the region, the drug concentration is above solubility. Let there be a moving boundary between
these two regions whose time varying location is given by x= s(t). As drug is released from the polymer
the moving boundary tracks back from the (initially fixed) boundary with the release medium to the
impermeable stent boundary. We assume that the dissolution is instantaneous so that the concentration
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on the moving boundary is equal to the solubility. Then the model is
Cp(x, t)=C0, 0 < x < s(t), 0 < t < t⋆, (3.1)
∂Cp
∂t
(x, t)=Dp
∂2Cp
∂x2
(x, t) s(t) < x < Lp, 0 < t < t⋆, (3.2)
Cp(s(t), t)=Cs, 0 < t < t⋆, (3.3)
Cp(Lp, t)= 0, 0 < t < t⋆, (3.4)
s(0)= Lp, 0 < t < t⋆, (3.5)
coupled with the Stefan-type boundary condition
− Dp
∂Cp
∂x
(s(t), t)= ds
dt
(Cs − C0). (3.6)
The problem is readily seen to have a similarity structure. If we let Cp(x, t)= F(ξ),
s(t)= Lp − θ
√
t and ξ = (Lp − x)/
√
t then the problem (3.1–3.6) becomes
Dp
d2F
dξ 2
(ξ)=−ξ
2
dF
dξ
(ξ), 0 < ξ < θ . (3.7)
F(0)= 0, (3.8)
F(θ)=Cs, (3.9)
Dp
dF
dξ
(θ)= θ
2
(C0 − Cs). (3.10)
The solution for t < t⋆ is (see Vo, 2012 or Paul & McSpadden, 1976):
Cp(x, t)=Cs
erf ((Lp − x)/2
√
Dpt)
erf (θ/2
√
Dp)
, s(t) < x < Lp, (3.11)
where θ is found by solving
2
√
Dp
π
Cs
C0 − Cs
= θ erf
(
θ
2
√
Dp
)
exp
{
θ2
4Dp
}
. (3.12)
Note t⋆ is known and is given by s(t⋆)= 0, i.e. t⋆ = (Lp/θ)2. The expression for the cumulative fraction
of drug released is found to be
Mfrac(t)=
√
t
LpC0
{
θ(C0 − Cs)+
2
√
DpCs(1− exp {−θ2/4Dp})√
π erf (θ/2
√
Dp)
}
, t < t⋆. (3.13)
Now, when all of the drug in the polymer is below solubility, the form of solution changes. At t= t⋆,
the concentration of drug in the polymer is clearly given by
Cp(x, t⋆)=Cs
erf ((Lp − x)/2
√
Dpt⋆)
erf (θ/2
√
Dp)
. (3.14)
 at U
niversity of Strathclyde on A
pril 17, 2014
http://im
am
m
b.oxfordjournals.org/
D
ow
nloaded from
 
RELEASE MECHANISM AND PARAMETER ESTIMATION IN DRUG-ELUTING STENT SYSTEMS 7 of 24
The solution for the duration of drug release is then obtained by solving (2.1), (2.3) and (2.4a) with
(3.14) replacing (2.2). Proceeding to solve by separation of variables, the concentration of the drug in
the polymer can be shown to be (see Appendix A)
Cp(x, t)=
4Cs
π erf (θ/2
√
Dp)
∞∑
n=1
(−1)n+1
2n− 1 cos
(
(2n− 1)πx
2Lp
)
exp
{−Dp(2n− 1)2π2
4Lp
t
}
×ℜ
{
erf
(
(2n− 1)iπDpt⋆ + Lp2
2Lp
√
Dpt⋆
)}
, (3.15)
where ℜ{z} denotes the real part of z. The corresponding expression for the cumulative fraction of drug
released for t > t⋆ (see Appendix A) is
Mfrac(t)= 1−
8Cs
C0π2 erf(θ/2
√
Dp)
×
∞∑
n=1
exp {(−Dp(2n− 1)2π2/4Lp)t}ℜ{erf(((2n− 1)iπDpt⋆ + L2p)/2Lp
√
Dpt⋆)}
(2n− 1)2 . (3.16)
Recall that t⋆ = (Lp/θ)2 where θ is given by (3.12).
3.2 Dissolution kinetics involving a first-order reaction
In the previous case we considered a situation where the dissolution of drug from crystalline into dis-
solved form is instantaneous. This may be reasonable where the volume of fluid available to dissolve
the drug is large. Consider now the case where the dissolution rate is finite, say K1. We will now denote
by Cb the bound drug which is in a crystalline form and Cf the free (dissolved) drug which is initially
zero. The model in this case is
∂Cf
∂t
(x, t)=Dp
∂2Cf
∂x2
(x, t)+ K1Cb(t), 0 < x < Lp, t > 0, (3.17)
dCb
dt
(t)=−K1Cb(t), 0 < x < Lp, t > 0, (3.18)
Cb(0)=C0b , 0  x  Lp, (3.19)
Cf(x, 0)= 0, 0  x  Lp, (3.20)
−Dp
∂Cf
∂x
(0, t)= 0, t > 0, (3.21)
Cf(Lp, t)= 0, t > 0. (3.22)
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The solution of the system (3.17–3.22) is detailed in Appendix B and is given by
Cb(t)=C0b exp {−K1t}, (3.23)
Cf(x, t)=
4K1C0b
π
∞∑
n=1
(−1)n+1 cos ((2n− 1)πx/2Lp)
(2n− 1)(K1 − (Dp/4L2p)(2n− 1)2π2)
×
{
exp
{
−Dp
4L2p
(2n− 1)2π2t
}
− exp {−K1t}
}
. (3.24)
The solution for the cumulative mass of drug released is
Mfrac(t)= 1− exp {−K1t} −
8K1
π2
∞∑
n=1
exp {(−Dp/4L2p)(2n− 1)2π2t} − exp {−K1t}
(2n− 1)2(K1 − (Dp/4L2p)(2n− 1)2π2)
. (3.25)
3.3 Dissolution kinetics involving a first-order reversible reaction
In this case we allow for a reversible reaction, i.e. the drug can dissolve from the crystalline form into
free form and also from free form into crystalline form. We assume that the forward reaction rate is K1
and the backward reaction is K2. The model in this case is
∂Cf
∂t
(x, t)=Dp
∂2Cf
∂x2
(x, t)+ K1Cb(x, t)− K2Cf(x, t), 0 < x < Lp, t > 0, (3.26)
∂Cb
∂t
(x, t)=−K1Cb(x, t)+ K2Cf(x, t) 0 < x < Lp, t > 0 (3.27)
coupled with (3.19–3.22). The solution as detailed in Appendix B is
Cf(x, t)=
K1C0bDpπ
L2p
2∑
j=1
∞∑
n=1
(−1)n(2n− 1)(sjn + K1)2 cos ((2n− 1)πx/2Lp)
(exp {sjn t} − exp {−(K2 + K1)t})
sjn(s
2
jn + 2K1sjn + K1(K2 + K1))(K2 + K1 + sjn)
, (3.28)
Cb(x, t)=C0b exp {−K1t} +
K2K1C0bDpπ
L2p
×
2∑
j=1
∞∑
n=1
⎧⎪⎪⎨
⎪⎪⎩
(−1)n(2n− 1)(sjn + K1)2 cos ((2n− 1)πx/2Lp)
sjn(s
2
jn + 2K1sjn + K1(K2 + K1))(K2 + K1 + sjn)
×
(
exp {sjn t} − exp {−K1t}
K1 + sjn
+ exp {−(K2 + K1)t} − exp {−K1t}
K2
)
⎫⎪⎪⎬
⎪⎪⎭ ,
(3.29)
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where
2s1n =−
(
K2 + K1 +
Dp
4L2p
π2(2n− 1)2
)
+
√
(K2 + K1 +
Dp
4L2p
π2(2n− 1)2)2 − K1Dp
L2p
π2(2n− 1)2,
2s2n =−
(
K2 + K1 +
Dp
4L2p
π2(2n− 1)2
)
−
√√√√(K2 + K1 + Dp4L2p π2(2n− 1)2
)2
− K1Dp
L2p
π2(2n− 1)2.
(3.30)
The cumulative fraction of drug released is then given by
Mfrac(t)= 1− exp {−K1t}
+ 2K2K1Dp
L2p
2∑
j=1
∞∑
n=1
(sjn + K1)2( exp {sjn t}−exp {−K1t}K1+sjn +
exp {−(K2+K1)t}−exp {−K1t}
K2
)
sjn(s
2
jn + 2K1sjn + K1(K2 + K1))(K2 + K1 + sjn)
+ 2K1Dp
L2p
2∑
j=1
∞∑
n=1
(sjn + K1)2(exp {sjn t} − exp {−(K2 + K1)t})
sjn(s
2
jn + 2K1sjn + K1(K2 + K1))(K2 + K1 + sjn)
. (3.31)
3.4 Graphical results
In this section we compare the release profiles obtained from the solutions to the diffusion–dissolution
models described in Sections 3.1–3.3. For each of the plots we assume typical values of the diffusion
coefficient and the polymer thickness, Dp = 10−16 m2 s−1 and Lp = 10−5 m, respectively, as in Section 2.
Figure 2 plots the cumulative percentage of drug released (Equations (3.13) and (3.16)) for the instan-
taneous dissolution model described in Section 3.1. We consider four different ratios of initial drug
concentration to solubility, C0/Cs = 10, 5, 2, 1. Figure 2 demonstrates that by increasing the fraction
C0/Cs, we can significantly prolong the duration of release. We note that when C0/Cs = 1, i.e. when the
initial drug concentration is not above solubility, we obtain a release profile identical to that provided
by (2.6) as expected.
Figure 3 plots the cumulative percentage of drug released (Equation (3.25)) for the first-order reac-
tion model described in Section 3.2. We consider three different values of K1, namely 10−4 s−1, 10−5 s−1
and 10−6 s−1, which correspond to Damkohler numbers (Da= L2pK1/Dp) of 100, 10 and 1. We demon-
strate that, as we reduce the Damkholer number (by reducing the value of K1), the release profile can
be significantly slowed down as diffusion becomes faster than reaction: in this case the system is thus
reaction-limited. In Fig. 4, we display the cumulative percentage of drug released (Equation (3.31))
for the first-order reversible reaction model described in Section 3.3. We choose K1 = 10−6 s−1 and
consider four different ratios of K1/K2, namely 100, 10, 1, 0.1 and demonstrate that in the case of a
reversible reaction, the release can also be significantly slowed down. Furthermore, we note that for
large K1/K2, the profile approaches that of the non-reversible reaction model. We note, too, that there is
a qualitative difference in the shape of the profile of the three different models.
4. Mechanism of drug release: the inverse problem
In Sections 2 and 3 we provided a series of analytical solutions to models which encompass diffusion-
and dissolution-based drug release. Here we test our models on in vitro experimental data that we have
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Fig. 2. Release profiles for the case of instantaneous dissolution. From top to bottom profiles C0/Cs increases from 1 to 2, 5 and
then 10. Solid lines indicate t < t⋆ while dotted lines indicate t > t⋆.
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Fig. 3. Release profiles for the case of non-reversible dissolution. As we reduce the Damkohler number, Da, we observe that the
release is slowed down.
obtained in our laboratory to try to ascertain the mechanism of release in a commercially available DES,
as well as estimating the model parameter(s) via the inverse problem. The experiments involved mea-
suring drug release from the Cypher DES. We have previously reported on the drug release from the
Cypher DES (McGinty et al., 2013). Briefly, the experiments consisted of placing four Cypher DESs in
separate sealed glass vials containing physiological release medium (phosphate buffered saline:ethanol
(90:10)). The experiments were carried out at 37◦C. At several time points up to 60 days, each stent was
removed and placed in a separate vial containing fresh release medium (to maintain perfect sink con-
ditions), with the mass of drug in the original solution subsequently quantified using UV-spectroscopy.
Solving an inverse problem consists of adjusting the parameters of a model function so as to best fit
the data set. In this case, the data set should be the experimentally measured mass of drug released
at various times. Adopting a least squares approach (and solving the resulting nonlinear equations via
Newton’s method), we find that drug release from the Cypher stent is best described by the diffu-
sion only model given by equations (2.1–2.4a). The best fitting value of the diffusion coefficient is
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Fig. 4. Release profiles for the case of reversible dissolution. Here K1 = 10−6 s−1 and we vary the value of K2. For K1/K2 1,
the effect of the reversible dissolution is relatively small, as expected. However, when K1/K2 < 1 so that the backward reaction
is faster than the forward reaction, the release may be significantly slowed down.
Dp = 6.3× 10−17 m2 s−1. Figure 5 displays a comparison between the experimentally measured cumu-
lative percentage of drug released, and the solution of (2.6). The good agreement between the model
and the experiments serves to demonstrate that diffusion is the dominant mechanism of release, at least
for this particular stent. For the case of the instantaneous diffusion model, the best fit was obtained
when C0/Cs=1, i.e. when the initial drug concentration is not above solubility. In this case the solution
is equivalent to (2.6). For the first-order reaction model, the best fit was obtained when the reaction rate,
K1, was so large that the dissolution could be considered instantaneous. Similarly, for the first-order
reversible reaction model, the best fit was obtained when K1 was very large and K2 very small, again
suggesting dissolution can be regarded as instantaneous, while also indicating a negligible backward
reaction.
5. Estimating physiological transport parameters
In many physiological processes, it is extremely difficult in practice to measure diffusion coefficients.
This is in part, at least, because there is often a small but significant convection flow; this is particularly
true near to arterial walls where there is a transmural pressure gradient and a consequent transmural
flow. In addition, the species diffusing may be consumed or lost from the system through such vehicles
as the vasa vasorum. In this section we indicate how a simple mathematical approach may allow the
diffusion coefficient to be uncoupled from these other effects.
5.1 Drug transport through the arterial wall
Consider the initial value problem
∂CT
∂t
(x, t)+ v∂CT
∂x
(x, t)=DT
∂2CT
∂x2
(x, t)− αCT(x, t) (5.1)
subject to
CT(x, 0)= 0, CT(0, t)=C0, t  0, CT(x, t) bounded for all x, t,
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Fig. 5. Comparison between in-vitro experimental data and diffusion based model of drug release from the Cypher stent (McGinty
et al., 2013).
where CT is the drug concentration in the tissue, C0 some constantly applied concentration, v the mag-
nitude of the transmural velocity, DT the diffusion coefficient in the tissue and drug is removed from
the system in proportion to α. For the case of the drug-eluting stent, the tissue is considered to be the
region (0 < x <∞) and while a constant applied concentration of drug at the polymer/media interface
is somewhat unrealistic, it may, nonetheless provide a good approximation for early times. A more
comprehensive model has been considered by Pontrelli and de Monte (2009), where the equation for
drug transport in the tissue (5.1) has been coupled with a diffusion equation for the release of drug from
the coating. Here, to effect comparisons with ex vivo experimental data, we restrict our attention to the
equation in the tissue.
Taking Laplace transforms of (5.1) and making use of the boundary conditions leads to
C¯T(x, s)=C0 exp
{
v
2DT
x
}
1
s
exp
⎧⎨
⎩− x√DT
√
s+ v
2
4DT
+ α
⎫⎬
⎭ . (5.2)
Now let x/
√
DT =
√
a and (v2/4DT)+ α = b, so that (5.2) can be written in the more concise form
C¯T(x, s)=C0 exp
{
v
2DT
x
}
1
s
exp{−
√
a(s+ b)}. (5.3)
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Applying Lemmas 1 and 2 (as detailed in Appendix C) directly provides two forms of the solution:
CT(x, t)=
C0
2
exp
{
v
2DT
x
}
×
⎡
⎢⎢⎢⎢⎣
exp
{
−x
√
v2
4D2T
+ α
DT
}
erfc
(
−
√(
v2
4DT
+ α
)
t + x
2
√
DTt
)
+ exp
{
x
√
v2
4D2T
+ αDT
}
erfc
(√(
v2
4DT
+ α
)
t + x
2
√
DTt
)
⎤
⎥⎥⎥⎥⎦ , (5.4)
CT(x, t)=C0 exp
{
v
2DT
x
}
×
⎡
⎢⎢⎣
exp
{
−
(
v2
4DT
+ α
)
t
}
erfc
(
1
2
x√
DTt
)
+
(
v2
4DT
+ α
)∫ t
0
exp
{
−
(
v2
4DT
+ α
)
τ
}
erfc
(
1
2
x√
DTτ
)
dτ
⎤
⎥⎥⎦ , (5.5)
where erfc is the complementary error function. Clearly, letting v,α→ 0 in (5.4) and (5.5), returns the
well known solution for the diffusion equation, that is
CT(x, t)=C0erfc
(
x
2
√
DTt
)
. (5.6)
The two forms of solution, (5.4) and (5.5), can be shown to be equivalent (see Appendix D) and further,
a third equivalent form of solution is given by
CT(x, t)=
2C0√
π
exp
{
v
2DT
x
}∫ ∞
x/2
√
DTt
exp
{
− x
2
4u2
(
v2
4D2T
+ α
DT
)
− u2
}
du. (5.7)
5.2 Inverse problem
The motivation for developing a solution to (5.1) was to allow the various model parameters to be
inferred via the inverse problem. The data set, in this case, should be a series of experimental tissue
concentration profiles where the drug transport is governed by convection as well as diffusion and drug
is lost from the system.
The data we would require to fit to our analytic solution do not appear to be available at present in
the literature. However, Creel et al. (2000) provide concentration profiles based on experiments which,
while admittedly do not account for drug loss (and thus render our parameter α redundant), do still
allow us to estimate DT and v. Figure 6 shows experimentally measured tissue paclitaxel concentra-
tion, normalized with respect to the applied endovascular concentration. The data are obtained from
experiments where arterial samples were perfused ex vivo for 15 min, 1 h and 4 h with a physiological
transmural pressure gradient. Paclitaxel was applied to the endovascular aspect of the artery in buffer
solution and drug distribution determined through en-face cryosectioning. In applying a least squares
approach, starting guesses of v= 10−8ms−1 and DT = 10−12 m2 s−1 (McGinty et al., 2010) result in con-
vergence of the least squares method to the values v= 1.8× 10−7 ms−1 and DT = 2.1× 10−13m2 s−1.
This result is particularly interesting, since despite an initial starting guess an order of magnitude lower,
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Fig. 6. Tissue concentration normalized by the endovascularly applied concentration as a function of time, in the presence of
physiological transmural hydrostatic pressure gradient. Reproduced from Creel, C. J., Lovich, M. A. & Edelman, E. R. (2000)
Arterial paclitaxel distribution and deposition. Circ. Res., 86, 874–884 with permission from Lippincott Williams & Wilkins.
Promotional and commerical use of the material in print, digital or mobile device format is prohibited without the permission
from the publisher Lippincott Williams & Wilkins. Please contact journalpermissions@lww.com for further information.
the parameter v converges to a value an order of magnitude higher while the parameter DT converges
to a value an order of magnitude lower. The initial guesses along with an assumed arterial thickness of
the order 10−4 m (McGinty et al., 2010), results in a Peclet numberO(1). However, the resulting Peclet
number from the least squares analysis is O(100). This only serves to demonstrate the importance of
accurate parameter estimation. While we have only been able to estimate v and DT from the experimen-
tal data available, the parameter α could also in principle be inferred if more appropriate experimental
data were available.
6. Conclusions
This paper has been concerned with release mechanisms and parameter estimation in drug-eluting stent
systems. Analytical solutions were obtained for mathematical models that were diffusion- and diffusion-
dissolution based. In addition, analytical solutions were also provided for dissolution kinetics involving
first-order reversible and non-reversible reactions. Experiments were performed in vitro and the subse-
quent data employed, via an inverse problem, to determine which of the models best fitted the in vitro
data. It was found that the simplest model, involving only diffusion, provided the best description of
in vitro drug release from the Cypher stent. However, it is anticipated that the other models developed
in this paper may well provide a better description of the release from different stent platforms. Finally,
a simple model of the transport of drug through the arterial wall was formulated; its analytical solution
was then employed using the existing data from Creel et al. (2000) to determine the underlying diffusion
coefficient and the transmural velocity through the arterial wall.
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Appendix A
In this appendix we consider the model defined in Section 3.1 and derive the expressions for the con-
centration of drug in the polymer and the cumulative fraction of drug released when the concentration
of drug in the polymer has dropped below the solubility. The model is stated as
∂Cp
∂t
(x, t)=Dp
∂2Cp
∂x2
(x, t), 0 < x < Lp, t > t⋆, (A.1)
−Dp
∂Cp
∂x
(0, t)= 0, t > t⋆, (A.2)
Cp(Lp, t)= 0, t > t⋆, (A.3)
Cp(x, t⋆)=Cs
erf ((Lp − x)/2
√
Dpt⋆)
erf (θ/2
√
Dp)
, 0 < x < Lp. (A.4)
Separation of variables results in the solution
Cp(x, t)=
∞∑
n=1
Bn cos
(
(n− 1/2)πx
Lp
)
exp
{
−Dp
(
(n− 1/2)π
Lp
)2
t
}
, (A.5)
where Bn (n= 1, 2, . . .) are constants to be determined. Imposing (A.4), multiplying through by
cos ((m− 1/2)πx/Lp) and integrating from 0 to Lp provides:
Cs
erf
(
θ
2
√
Dp
) ∫ Lp
0
erf
(
Lp − x
2
√
Dpt⋆
)
cos
(
(m− 1/2)πx
Lp
)
dx
=
∞∑
n=1
Bn exp
{
−Dp
(
(n− 1/2)π
Lp
)2
t⋆
}∫ Lp
0
cos
(
(n− 1/2)πx
Lp
)
cos
(
(m− 1/2)πx
Lp
)
dx.
(A.6)
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Consider firstly the integral on the left-hand side of (A.6):
∫ Lp
0
erf
(
Lp − x
2
√
Dpt⋆
)
cos
(
(m− 1/2)πx
Lp
)
dx
= 2√
π
∫ Lp
0
∫ (Lp−x)/2√Dpt⋆
0
exp {−z2} dz cos
(
(m− 1/2)πx
Lp
)
dx
= 2Lp
(m− 1/2)π3/2
∫ Lp/2√Dpt⋆
0
exp {−z2} sin
(
(m− 1/2)π − 2(m− 1/2)π
Lp
√
Dpt⋆z
)
dz, (A.7)
on interchanging the integrals and performing the internal integration. Writing sine in terms of cosine
in (A.7) and performing the integration results in
2Lp
(m− 1/2)π3/2
∫ Lp/2√Dpt⋆
0
exp {−z2} sin
(
(m− 1/2)π − 2(m− 1/2)π
Lp
√
Dpt⋆z
)
dz
= 2Lp(−1)
m+1
(m− 1/2)π3/2
∫ Lp/2√Dpt⋆
0
exp {−z2} cos
(
(2m− 1)π
Lp
√
Dpt⋆z
)
dz
= (−1)
m+2Lp
(2m− 1)π exp
{
− (m− 1/2)
2π2Dpt⋆
L2p
}⎧⎪⎪⎨
⎪⎪⎩
erf
(
(2m−1)iπDpt⋆−L2p
2Lp
√
Dpt⋆
)
− erf
(
(2m−1)iπDpt⋆+L2p
2Lp
√
Dpt⋆
)
⎫⎪⎪⎬
⎪⎪⎭ . (A.8)
Thus, returning to (A.6), and making use of orthogonality:
Bn =
2Cs(−1)n+2
(2n− 1)π erf (θ/2√Dp)
{
erf
(
(2n− 1)iπDpt⋆ − L2p
2Lp
√
Dpt⋆
)
− erf
(
(2n− 1)iπDpt⋆ + L2p
2Lp
√
Dpt⋆
)}
.
(A.9)
Noting that
erf (−z¯)− erf (z)=−2ℜ{erf (z)},
we may write (A.9) as
Bn =
4Cs(−1)n+1
(2n− 1)π erf (θ/2√Dp)ℜ
{
erf
(
(2n− 1)iπDpt⋆ + L2p
2Lp
√
Dpt⋆
)}
. (A.10)
Substitution of (A.10) into (A.5) provides the solution as (3.15). Now, the cumulative fraction of drug
released is given by
Mfrac(t)= 1−
M (t)
M0
, (A.11)
where M (t)= ∫ Lp0 Cp(x, t) dx is the mass of drug per unit area and M0 = LpC0. Evaluating the integra-
tion, the solution is readily seen to be (3.16).
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Appendix B
In this appendix we provide an outline of the solution of the model presented in Section 3.3. The model
presented in Section 3.2 is then shown to be a special case and we deduce the solution by taking the limit
as K2 → 0. Consider the model of drug release by dissolution and diffusion as presented in Section 3.3:
∂Cf
∂t
(x, t)=DP
∂2Cf
∂x2
(x, t)+ K1Cb(x, t)− K2Cf(x, t), 0 < x < Lp, t > 0, (B.1)
∂Cb
∂t
(x, t)=−K1Cb(x, t)+ K2Cf(x, t), 0 < x < Lp, t > 0, (B.2)
Cb(x, 0)=C0b , 0  x  Lp, (B.3)
Cf(x, 0)= 0, 0  x  Lp, (B.4)
−Dp
∂Cf
∂x
(0, t)= 0, t > 0, (B.5)
Cf(Lp, t)= 0, t > 0. (B.6)
Solving (B.2) subject to (B.3) provides
Cb(x, t)=K2
∫ t
0
exp {−K1(t − τ)}Cf(x, τ) dτ + C0b exp {−K1t}. (B.7)
Substitution of (B.7) into (B.1) and taking Laplace transforms we find that
d2C¯f
dx2
(x, s)− Γ 2(s)=− K1C
0
b
Dp(s+ K1)
, (B.8)
where use has been made of (B.4), the overbar denotes the transformed variable, and
Γ 2(s)= s(s+ K2 + K1)
Dp(s+ K1)
. (B.9)
Solving (B.8) subject to the conditions (B.5–B.6) yields
C¯f(x, s)=
K1C0b
s+ K2 + K1
(
cosh (Γ (s)Lp)− cosh (Γ (s)x)
s cosh (Γ (s)Lp)
)
. (B.10)
We note that
L−1
[
K1C0b
s+ K2 + K1
]
=K1C0b exp {−(K2 + K1)t}. (B.11)
Consider now
L−1
[
cosh (Γ (s)Lp)− cosh (Γ (s)x)
s cosh (Γ (s)Lp)
]
. (B.12)
By series expansion (or otherwise) it can be shown that expression (B.11) has no branch points. Further-
more, the apparent singularities at s= 0 and s=−K1 are actually removable. Any other singularities
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must be such that
cosh (Γ (s)Lp)= 0. (B.13)
By writing the hyperbolic cosine in terms of exponentials it is readily seen that the roots of (B.13) must
satisfy
Γ (s)Lp = iπ(n− 12 ), n=±(1, 2, 3, . . .). (B.14)
Thus we have a countably infinite number of singularities. We proceed to invert (B.11) by use of the
Residue Theorem. Substituting the expression for Γ from (B.9) into (B.14) we see that the roots must
satisfy the quadratic:
s2 +
(
K2 + K1 +
Dp
4L2p
π2(2n− 1)2
)
s+ Dp
4L2p
π2(2n− 1)2K1 = 0. (B.15)
The roots s1n and s2n are given by (3.30) from which we note that they all lie to the left of s= 0. The
residues are thus given by
2∑
j=1
∞∑
n=1
lim
s→sjn
{
s− sjn
cosh (Γ Lp)
}
lim
s→sjn
{
(cosh (Γ Lp)− cosh (Γ x)) exp {st}
s
}
. (B.16)
Making use of L’Hopital’s rule, (B.16) becomes
2∑
j=1
∞∑
n=1
(−1)nDp(2n− 1)π(sjn + K1)2 cos ((2n− 1)πx/2Lp) exp {sjn t}
L2psjn(s2jn + 2K1sjn + K1(K2 + K1))(K2 + K1 + sjn)
. (B.17)
Utilizing (B.11) and (B.17) along with convolution, the Laplace transform of (B.10) is
Cf(x, t)=
K1C0bDpπ
L2p
∫ t
0
exp {−(K2 + K1)(t − τ)}
×
2∑
j=1
∞∑
n=1
(−1)n(2n− 1)(sjn + K1)2 cos ((2n− 1)πx/2Lp) exp {sjnτ }
sjn(s
2
jn + 2K1sjn + K1(K2 + K1))(K2 + K1 + sjn)
dτ . (B.18)
Evaluating the integral in (B.18) we obtain the solution (3.28). Furthermore, substitution of (3.28) into
(B.7) provides the solution of bound drug concentration (3.29). The expression for the cumulative frac-
tion of drug released is given by
Mfrac(t)= 1−
M (t)
M0
, (B.19)
where M0 = LpC0b and
M (t)=
∫ Lp
0
Cb(x, t) dx+
∫ Lp
0
Cf(x, t) dx. (B.20)
Evaluation of the integrals in (B.20) and substitution into (B.19) provides the solution of cumulative
fraction of drug released as given by (3.31).
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Now, it is readily seen that the model defined by (B.1–B.6) can be reduced to the model defined by
(3.17–3.22) by letting K2 → 0. Taking this limit in (B.9),
Γ 2(s)→ s
Dp
, (B.21)
so that, by (B.14),
s=−Dp
L2p
π2
(
n− 1
2
)2
, n=±(1, 2, 3, . . .) (B.22)
are the singularities. In this limit,
C¯f(x, s)=
K1C0b
s+ K1
(
cosh (
√
(s/Dp)Lp)− cosh (
√
(s/Dp)x)
s cosh (
√
(s/Dp)Lp)
)
. (B.23)
Using the Residue Theorem as before, the solution is given by (3.24) and the corresponding expression
for the cumulative fraction of mass released is given by (3.25).
Appendix C
The following lemmas have to be used while solving Equation (5.1).
Lemma C.1 Let f (t) be any continuous function and let f¯ (s)= L[f (t)] be its corresponding Laplace
transform. Then if
f¯ (s)= 1
s
exp{−
√
a(s+ b)},
then
f (t)= 1
2
[
exp{−
√
ab} erfc
(
−
√
bt + 1
2
√
a
t
)
+ exp{
√
ab} erfc
(√
bt + 1
2
√
a
t
)]
.
Proof. Note that one can write
1
s
exp{−
√
a(s+ b)} =
[ −1√
s+ b+
√
b
+ 1√
s+ b−
√
b
]
exp{−√a(s+ b)}
2
√
b
. (C.1)
Employing the Shifting Theorem, L−1[f¯ (s+ b)]= exp{−bt}L−1[f¯ (s)]= exp{−bt}f (t), results in
L−1
[
1
s
exp{−
√
a(s+ b)}
]
= exp{−bt}
2
√
b
L−1
[{
1√
s−
√
b
− 1√
s+
√
b
}
exp{−√as}
]
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= exp{−bt}
2
√
b
×
⎡
⎢⎢⎣
1√
π t
exp
{
− a
4t
}
+
√
b exp{−
√
ab} exp{bt} erfc
(
−
√
bt + 1
2
√
a
t
)
−
(
1√
π t
exp
{
− a
4t
}
−
√
b exp{
√
ab} exp{bt} erfc
(√
bt + 1
2
√
a
t
))
⎤
⎥⎥⎦
= 1
2
[
exp{−
√
ab} erfc
(
−
√
bt + 1
2
√
a
t
)
+ exp{
√
ab} erfc
(√
bt + 1
2
√
a
t
)]
. (C.2)

Lemma C.2 Let f (t) be any continuous function and let f¯ (s)= L[f (t)] be its corresponding Laplace
transform. Then if
f¯ (s)= 1
s
exp{−
√
a(s+ b)},
then
f (t)= exp{−bt} erfc
(
1
2
√
a
t
)
+ b
∫ t
0
exp{−bτ } erfc
(
1
2
√
a
τ
)
dτ .
Proof. It is well established that L−1[exp{−√as}/s)]= erfc(√(a/t)/2). Also, from the first Shifting
Theorem:
L−1
[
1
s+ b exp{−
√
a(s+ b)}
]
= exp{−bt}L−1
[
1
s
exp{−√as}
]
. (C.3)
Now
1
s
=
(
1+ b
s
)
1
s+ b (C.4)
so that
L−1
[
1
s
exp{−
√
a(s+ b)}
]
= L−1
[(
1+ b
s
)
1
s+ b exp{−
√
a(s+ b)}
]
=
∫ t
0
[δ(t − τ)+ b] exp{−bτ } erfc
(
1
2
√
a
τ
)
dτ
= exp{−bt} erfc
(
1
2
√
a
t
)
+ b
∫ t
0
exp{−bτ } erfc
(
1
2
√
a
τ
)
dτ . (C.5)

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Appendix D
The two forms of solution, (5.4) and (5.5), can be shown to be equivalent. Consider firstly the results
from Lemmas 1 and 2:
L−1
[
1
s
exp
{√
a(s+ b)
}]
= 1
2
[
exp{−
√
ab} erfc
(
−
√
bt + 1
2
√
a
t
)
+ exp{
√
ab} erfc
(√
bt + 1
2
√
a
t
)]
. (D.1)
L−1
[
1
s
exp{
√
a(s+ b)}
]
= exp{−bt} erfc
(
1
2
√
a
t
)
+ b
∫ t
0
exp{−bτ } erfc
(
1
2
√
a
τ
)
dτ . (D.2)
Recall the definition of erfc(z)
erfc(z)= 2√
π
∫ ∞
z
exp{−u2} du. (D.3)
Consider
erfc
(
A
k
+ Bk
)
= 2√
π
∫ ∞
A/k+Bk
exp{−u2} du. (D.4)
Now, differentiating (D.4) with respect to k provides (making use of Leibnitz rule)
d
dk
[
erfc
(
A
k
+ Bk
)]
=− 2√
π
exp
{
−
(
A
k
+ Bk
)2}(
B− A
k2
)
=− 2√
π
(
B− A
k2
)
exp{−2AB} exp
{
−
(
A
k
)2
− (Bk)2
}
. (D.5)
Similarly,
d
dk
[
erfc
(
A
k
− Bk
)]
=− 2√
π
(
−B− A
k2
)
exp{2AB} exp
{
−
(
A
k
)2
− (Bk)2
}
. (D.6)
Thus one may write
exp{2AB} d
dk
[
erfc
(
A
k
+ Bk
)]
− exp{−2AB} d
dk
[
erfc
(
A
k
− Bk
)]
=− 4B√
π
exp
{
−
(
A
k
)2
− (Bk)2
}
. (D.7)
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Noting that −erfc(z)= erfc(−z), it then follows that
exp{2AB}
∫ ∞
(1/2)
√
(a/t)
d
dk
erfc
(
A
k
+ Bk
)
dk
+ exp{−2AB}
∫ ∞
(1/2)
√
(a/t)
d
dk
erfc
(
−A
k
+ Bk
)
dk
=− 4B√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
−
(
A
k
)2
− (Bk)2
}
dk. (D.8)
Simplifying (D.8) provides
exp{2AB}
[
erfc(∞)− erfc
(
2A
√
t√
a
+ B
√
a
2
√
t
)]
+ exp{−2AB}
[
erfc(∞)− erfc
(
−2A
√
t√
a
+ B
√
a
2
√
t
)]
=− 4B√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
−
(
A
k
)2
− (Bk)2
}
dk. (D.9)
Noting that erfc(∞)= 0, Equation (D.9) can be simplified further to give
1
2
[
exp{2AB} erfc
(
2A
√
t√
a
+ B
√
a
2
√
t
)
+ exp{−2AB} erfc
(
−2A
√
t√
a
+ B
√
a
2
√
t
)]
= 2B√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
−
(
A
k
)2
− (Bk)2
}
dk. (D.10)
Making the substitution B= 1, A=
√
ab/2 in (D.10) results in the following expression:
1
2
[
exp{−
√
ab} erfc
(
−
√
bt + 1
2
√
a
t
)
+ exp{
√
ab} erfc
(√
bt + 1
2
√
a
t
)]
= 2√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
− ab
4k2
− k2
}
dk, (D.11)
whose right-hand side is a further characterization of the inverse Laplace transform:
L−1
[
1
s
exp{
√
a(s+ b)}
]
= 2√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
− ab
4k2
− k2
}
dk. (D.12)
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Using (D.3), Equation (D.2) can be manipulated as follows:
exp{−bt} erfc
(
1
2
√
a
t
)
+ b
∫ t
0
exp{−bτ } erfc
(
1
2
√
a
τ
)
dτ
= exp{−bt} erfc
(
1
2
√
a
t
)
+ 2b√
π
∫ ∞
(1/2)
√
(a/t)
∫ t
a/4u2
exp{−bτ − u2} dτ du
= exp{−bt}
[
erfc
(
1
2
√
a
t
)
− 2√
π
∫ ∞
(1/2)
√
(a/t)
exp{−u2} du
]
+ 2√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
− ab
4u2
− u2
}
du
= 2√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
− ab
4u2
− u2
}
du. (D.13)
Making use of (D.11) and (D.13), one can write down the three equivalent forms:
L−1
[
1
s
exp{
√
a(s+ b)}
]
= 1
2
[
exp{−
√
ab} erfc
(
−
√
bt + 1
2
√
a
t
)
+ exp{
√
ab} erfc
(√
bt + 1
2
√
a
t
)]
= exp{−bt} erfc
(
1
2
√
a
t
)
+ b
∫ t
0
exp{−bτ } erfc
(
1
2
√
a
τ
)
dτ
= 2√
π
∫ ∞
(1/2)
√
(a/t)
exp
{
− ab
4u2
− u2
}
du. (D.14)
Thus, a third form of solution for drug concentration in the tissue is given by
CT(x, t)=
2C0√
π
exp
{
v
2DT
x
}∫ ∞
(1/2)
√
(a/t)
exp
{
− ab
4u2
− u2
}
du. (D.15)
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